Enclomifene Immediate Release Capsule for Testosterone Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for testosterone deficiency, particularly those using non-steroidal selective estrogen receptor modulators (SERMs), face challenges such as ineffective administration routes, adverse side effects, and a lack of understanding regarding the pharmacological effects of stereoisomers like enclomifene and zuclomiphene.
Innovation Solution
The development of immediate delivery (ID) capsules containing enclomifene, the (E)-stereoisomer of clomifene, which provides a more effective treatment for testosterone deficiency compared to traditional slow-release oral tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional slow-release oral tablets are used for SERM administration, then chronic daily administration is achieved, but treatment effectiveness is reduced and side effects increase
Solution Approach 1:
The patent changes the administration parameter from slow-release chronic daily to immediate release as needed. This parameter change in the dosage form formulation leads to improved treatment effectiveness while reducing side effects such as gynecomastia, weight gain, and hair loss associated with traditional SERM administration.
Solution Approach 2:
The patent implements periodic action by allowing as-needed administration rather than continuous chronic daily administration. This periodic dosing approach maintains treatment effectiveness while minimizing cumulative side effects through reduced overall exposure duration.
2Speed
If clomifene is administered as slow-release oral tablets, then chronic daily administration is achieved, but rapid response is not obtained
Solution Approach 1:
The patent changes the release parameter from slow-release to immediate release, enabling rapid response to treatment while reducing the time required for administration. The immediate release formulation allows the SERM to act quickly without the delayed onset associated with slow-release tablets.
3Ease of manufacture
If traditional SERM formulations are used, then chronic administration is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent simplifies the formulation by changing from complex slow-release tablet formulations to simpler immediate release capsule formulations. This parameter change in the dosage form reduces manufacturing complexity while maintaining therapeutic effectiveness.
Data Source
AI summary
In various embodiments compositions for the treatment of testosterone deficiency (TD, or “low-T”) and/or secondary hypogonadotropic hypogonadism comprise at least one selective estrogen receptor modulator (SERM) and a carrier, wherein the composition is entirely devoid of any estrogenically active substances capable of lowering testosterone levels. In preferred embodiments, compositions comprise only the (E)-stereoisomer of clomiphene and are entirely devoid of the estrogenically active (Z)-stereoisomer of clomiphene. In various examples, compositions are enclosed in a rapidly disintegrating capsule configured for immediate release. In preferred embodiments, the carrier comprises microcrystalline cellulose that functions as both bulk filler and disintegrant.